Serotonin 5-HT6 receptor antagonists for the treatment of Alzheimer's disease.
Recently, the serotonin 5-HT(6) receptor has been identified as a drug target for attenuating cognitive deficits associated with Alzheimer's disease (AD). Additionally, this receptor may also play a role in schizophrenia, anxiety and obesity. Reports in the literature suggest that the production of selective antagonists for the 5-HT(6) receptor has increased during the last 10 years, with some compounds currently in clinical trials for the treatment of AD. In this review, we will address the rationale for using 5-HT(6) receptor antagonists in AD, as well as report on current advances in the understanding of the structure-activity relationships required to synthesize 5-HT(6) receptor antagonists.
Geldenhuys
Werner J
WJ
Department of Pharmaceutical Sciences, Northeastern Ohio Universities Colleges of Medicine and Pharmacy, Rootstown, OH 44272, USA.
Van der Schyf
Cornelis J
CJ
D000544:Alzheimer Disease / Q000188:drug therapy*; D006801:Humans; D015394:Molecular Structure; D018697:Nootropic Agents / Q000737:chemistry / Q000627:therapeutic use*; D011985:Receptors, Serotonin / Q000378:metabolism*; D012702:Serotonin Antagonists / Q000737:chemistry / Q000627:therapeutic use*
D018697:Nootropic Agents; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; C097216:serotonin 6 receptor